The Sabin-Aspen Vaccine Science & Policy Group convened in 2018 to explore challenges and opportunities to develop a universal influenza vaccine. The group’s recommendations on how to overcome the scientific, financial and organizational barriers to developing a vaccine are synthesized in the report Accelerating the Development of a Universal Influenza Vaccine.
Vaccines have saved more lives than any other medical advance in recent history. However, falling immunization rates puts this progress at risk. Share the importance of immunization with colleagues or patients with this simple infographic in English and Romanian.
Immunization is among the most impactful and cost-effective health investments a nation can make. However, with the introduction of new vaccines, the cost to vaccinate a child continues to rise. Many low- and middle-income countries that currently receive financial support for their immunization programs will no longer be eligible by 2020 due to their growing economies, and must therefore transition away from external financing and toward country ownership.
In light of rising outbreaks of measles and other vaccine-preventable diseases in Europe, the Sabin Vaccine Institute in 2018 conducted a review of immunization legislation in the region.
Streptococcus pneumoniae remains an important cause of pneumonia and invasive bacterial disease, primarily meningitis and sepsis. The greatest burden of disease occurs in low-and middle-income countries, and the risk of serious pneumococcal disease peaks at the extreme ages of life. Young children are at highest risk, but older adults and people with immuno-compromising conditions also suffer high rates of pneumococcal disease.